Research Analysts’ Weekly Ratings Changes for MDxHealth (MDXH)

Several brokerages have updated their recommendations and price targets on shares of MDxHealth (NASDAQ: MDXH) in the last few weeks:

• 5/16/2026 – MDxHealth was downgraded by Wall Street Zen from “hold” to “strong sell”.
• 5/14/2026 – MDxHealth had its “buy” rating reaffirmed by TD Cowen. They now have a $1.50 price target on the stock, down from $7.00.
• 5/14/2026 – MDxHealth had its price target lowered by Lake Street Capital from $9.00 to $5.00. They now have a “buy” rating on the stock.
• 5/14/2026 – MDxHealth was downgraded by William Blair from “outperform” to “market perform”.
• 5/14/2026 – MDxHealth had its price target lowered by BTIG Research from $7.00 to $4.00. They now have a “buy” rating on the stock.
• 3/27/2026 – MDxHealth had its “sell (d-)” rating reaffirmed by Weiss Ratings.

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.